AMnESTI reverses age-associated lung immune decline to drive heterosubtypic protection by inactivated influenza vaccines.

AMnESTI restores aged lung immunity to enable complete heterosubtypic protection by influenza vaccines in elderly mice.

• Why it matters: Elderly populations have limited responses to current influenza vaccines, increasing their vulnerability to diverse influenza strains and severe illness.
• What they did: Researchers developed AMnESTI, a liposome-based STING agonist targeting alveolar epithelial cells, and tested its ability to boost immune responses in aged mice using single-cell RNA sequencing and flow cytometry.
• The result: A single intranasal dose of AMnESTI-adjuvanted vaccine fully protected aged mice against multiple influenza strains, demonstrating that transient immune reprogramming can enhance vaccine efficacy in the elderly.